Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Terremoto Biosciences Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07109726CT.gov A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | — | Recruiting | — | — | — |
NCT07038369CT.gov A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | — | Active Not Recruiting | — | — | — |
NCT06257264CT.gov A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | — | Active Not Recruiting | — | — | — |
NCT05867251CT.gov Study of AVZO-021 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05564377CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | — | Recruiting | — | — | — |
NCT05082025CT.gov Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | — | Terminated | — | — | — |
NCT05252416CT.gov (VELA) Study of BLU-222 in Advanced Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fulvestrant (this asset) | Terremoto Biosciences Inc. | P2 | B · 57 |
| Indocyanine Green | Istanbul University | P4 | BB |
| Adriamycin | AstraZeneca | P3 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Olaparib | Qilu Pharmaceutical Co., Ltd. | P4 | BB |
| Nivestim | Mayo Clinic | P3 | B |
| Patent Blue Violet | Centre Oscar Lambret | P3 | B |
| Pembrolizumab | Eikon Therapeutics | P3 | B |
| Docetaxel | Merck Sharp & Dohme LLC | P3 | B |
+42 more in the Endometrial Carcinoma cohort
Other indications for Fulvestrant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BB · 70 |
| Breast Cancer | — | P4 | BB · 69 |
| Invasive Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fulvestrant in Endometrial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fulvestrant-endometrial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →